Isomorphic Labs Raises $600M in First External Funding Round
Summary
Isomorphic Labs, the Alphabet spinout building AI-native drug discovery on the AlphaFold platform, raised $600 million in its first external funding round. Led by Thrive Capital with participation from GV (Google Ventures), the round marked the company's transition from a wholly owned Alphabet subsidiary to an independent entity with outside investors — a structural shift that placed it in direct competition with biotech startups rather than being subsidized as an Alphabet moonshot.
What Happened
Isomorphic Labs was founded in 2021 as a DeepMind spinout with a mandate to apply AlphaFold's structural biology insights to drug discovery. For its first four years it operated without external capital, funded entirely through Alphabet. The March 2025 raise changed that equation. Thrive Capital — the venture firm known for leading late-stage technology bets including OpenAI — led the round, with Google Ventures co-investing alongside undisclosed strategic partners.
The company disclosed two anchor pharma partnerships: Eli Lilly and Novartis, both announced in late 2024, involving milestone-and-royalty structures for AI-designed drug candidates in oncology and immunology. These deals gave Isomorphic Labs a path to revenue that pure-platform AI companies lacked, while the $600M raise provided runway to advance its internal pipeline toward clinical trials independently of partner timelines.
The technical foundation was AlphaFold 3, published in Nature in May 2024, which extended structure prediction from proteins alone to protein-ligand, protein-nucleic acid, and protein-small-molecule complexes — the configurations most relevant to drug design. Isomorphic had access to AlphaFold 3 before its public release and built its internal screening and optimization pipeline on top of it.
Why It Matters
The round crystallized the post-AlphaFold commercial landscape. Protein structure prediction had been a research problem for 50 years; its solution created a platform on which an entire drug discovery paradigm could be rebuilt. The question was whether the performance gains in structure prediction would translate to actual drugs reaching patients, a process with a decade-plus timeline and brutal attrition rates.
Isomorphic's $600M raise, at an undisclosed but implied multi-billion-dollar valuation, reflected investor belief that the platform advantage was real and defensible. The competing hypothesis — that AlphaFold 3 was a commodity tool that would quickly be matched by open alternatives and that Isomorphic's lead would erode — was already being tested by the proliferation of open-source alternatives like Boltz-2 (released June 2025). How the commercial and academic tracks diverge from a common AlphaFold origin will define AI-native pharma's first decade.